AbbVie Inc (ABBV)vsNovo Nordisk A/S (NVO)
ABBV
AbbVie Inc
$263.78
-0.02%
HEALTHCARE · Cap: $454.36B
NVO
Novo Nordisk A/S
$43.24
+0.12%
HEALTHCARE · Cap: $205.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 412% more annual revenue ($329.43B vs $64.39B). NVO leads profitability with a 35.3% profit margin vs 9.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
NVO
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$263.78
$111.62 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 42.5%
Generating 42.4B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
2.1% revenue growth
Weak financial health signals
Expensive relative to growth rate
Earnings declined 20.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 35.3% and operating margin at 42.5%.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : NVO
The primary concerns for NVO are Revenue Growth, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
NVO carries more volatility with a beta of 0.34 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
NVO generates stronger free cash flow (42.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 58/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?